Abstract

Background: Antipsychotic-induced metabolic syndrome (MetS) is a multifactorial disease with a genetic predisposition. Serotonin and its receptors are involved in antipsychotic-drug-induced metabolic disorders. The present study investigated the association of nine polymorphisms in the four 5-hydroxytryptamine receptor (HTR) genes HTR1A, HTR2A, HTR3A, and HTR2C and the gene encoding for the serotonin transporter SLC6A4 with MetS in patients with schizophrenia. Methods: A set of nine single-nucleotide polymorphisms of genes of the serotonergic system was investigated in a population of 475 patients from several Siberian regions (Russia) with a clinical diagnosis of schizophrenia. Genotyping was performed and the results were analyzed using chi-square tests. Results: Polymorphic variant rs521018 (HTR2C) was associated with higher body mass index in patients receiving long-term antipsychotic therapy, but not with drug-induced metabolic syndrome. Rs1150226 (HTR3A) was also associated but did not meet Hardy–Weinberg equilibrium. Conclusions: Our results indicate that allelic variants of HTR2C genes may have consequences on metabolic parameters. MetS may have too complex a mechanistic background to be studied without dissecting the syndrome into its individual (causal) components.

Highlights

  • Antipsychotics are important therapeutic agents for patients with schizophrenia, but long-term use of these drugs increases the risk of developing type 2 diabetes mellitus, hyperlipidemia, and hypertension [1,2,3,4,5,6]

  • These drugs are known to increase the prevalence of metabolic syndrome (MetS), which is a clustering of well-known cardiovascular risk factors and is known to be augmented in a variety of psychiatric disorders [6]

  • Metabolic syndrome was diagnosed in 126 patients (26.5%)

Read more

Summary

Introduction

Antipsychotics are important therapeutic agents for patients with schizophrenia, but long-term use of these drugs increases the risk of developing type 2 diabetes mellitus, hyperlipidemia, and hypertension [1,2,3,4,5,6] These drugs are known to increase the prevalence of metabolic syndrome (MetS), which is a clustering of well-known cardiovascular risk factors and is known to be augmented in a variety of psychiatric disorders [6]. The present study investigated the association of nine polymorphisms in the four 5-hydroxytryptamine receptor (HTR) genes HTR1A, HTR2A, HTR3A, and HTR2C and the gene encoding for the serotonin transporter SLC6A4 with MetS in patients with schizophrenia. Results: Polymorphic variant rs521018 (HTR2C) was associated with higher body mass index in patients receiving long-term antipsychotic therapy, but not with drug-induced metabolic syndrome. MetS may have too complex a mechanistic background to be studied without dissecting the syndrome into its individual (causal) components

Methods
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.